Uzbekistan Digital Health Platform - Integrations
0.12.1 - draft
This page is part of the Uzbekistan Digital Health Platform - Integrations (v0.12.1: Releases Draft) based on FHIR (HL7® FHIR® Standard) v5.0.0. This is the current published version. For a full list of available versions, see the Directory of published versions
Joriy sahifa uchun tarjima sahifasi mavjud emas, shuning uchun u standarttilida ko‘rsatildi
Volume 6 covers the "mother and child" screening programme: checking an unborn baby for serious conditions during pregnancy, and checking a newborn in its first days of life. It is run in dedicated screening centres and is closely tied to ordinary pregnancy care in volume 2 and the birth itself in volume 1.
Screening means testing people who seem healthy to catch hidden problems early. This volume has two distinct halves, joined by the birth:
The important idea for a non-expert is that screening is a funnel: many people are screened, a few are flagged, and only those few go on to the definitive tests. The forms follow that funnel.
The prenatal track is a decision chain. The exam card (159) opens the file. The trimester ultrasound (162-164) and biochemical screening (156-157) produce a risk estimate. A high risk leads to a counselling step where the mother either consents (152, 153) or refuses (155). Consent unlocks the invasive procedure (166), which produces a cytogenetic result (154), which feeds the genetic conclusion (165, 172) and, in difficult cases, a panel discussion called a perinatal consilium (173). Each step gates the next, so the forms are genuinely sequential.
The neonatal track is a shorter chain: the heel-prick screen (167) leads, only if abnormal, to confirmatory tests (168, 170) and a retest (171).
A third small group is the registry for people already known to have a hereditary disease (158) and their specialist check-ups (160, 161).
The diagram shows the two tracks and the consent gate between screening and the invasive test:
Imagine a woman early in pregnancy, referred from her polyclinic (037-1) to the screening centre, where an exam card is opened (159). Her first-trimester ultrasound (162) and blood screen (156) come back showing an increased chance of a chromosomal condition. A counsellor explains the options, and she decides to go ahead with the definitive test, signing a consent form (152). The procedure is done (166) and the laboratory examines the baby's chromosomes (154). The result is discussed by a panel (173) and a genetic conclusion is issued (165). Months later, after a healthy birth, the newborn has the routine heel-prick screen (167), which is normal, and no further action is needed.
The sequence below traces that pathway, including the point where a mother might decline:
This is the screening portion of the wider maternity journey that also spans volumes 2 and 1.
| Form | Title | Type |
|---|---|---|
| 152, 153 | Informed consent for invasive prenatal diagnosis | Consent |
| 154 | Cytogenetic / molecular-cytogenetic result | Report |
| 155 | Refusal of invasive prenatal diagnosis | Statement |
| 156, 157 | First / second trimester biochemical screening conclusion | Conclusion |
| 158 | Hereditary-genetic patient ambulatory card | Card |
| 159 | Pregnant woman prenatal examination card | Card |
| 160, 161 | Genetic patient consults (neuropathologist, endocrinologist) | Card |
| 162, 163, 164 | First / second / third trimester ultrasound screening protocol | Report |
| 165 | Medical genetic conclusion | Conclusion |
| 166 | Invasive prenatal diagnosis procedure protocol | Report |
| 167 | Neonatal screening (IRT, PKU, congenital hypothyroidism) | Analysis |
| 168 | Tandem mass-spectrometry analysis | Analysis |
| 169 | Clinical-diagnostic laboratory IXLA analysis | Analysis |
| 170 | Sweat test | Analysis |
| 171 | Neonatal retest screening | Analysis |
| 172 | Post-invasive-diagnosis conclusion | Conclusion |
| 173 | Perinatal consilium | Conclusion |
| 174 | Pre-surgery epicrisis for a pregnant woman | Epicrisis |